title: Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels.
abstract: BACKGROUND
  Alzheimer's disease (AD) is characterized by a decline in cognitive function and accumulation of amyloid-beta peptide (Abeta) in extracellular plaques. Mutations in amyloid precursor protein (APP) and presenilins alter APP metabolism resulting in accumulation of Abeta42, a peptide essential for the formation of amyloid deposits and proposed to initiate the cascade leading to AD. However, the role of Abeta40, the more prevalent Abeta peptide secreted by cells and a major component of cerebral Abeta deposits, is less clear. In this study, virally-mediated gene transfer was used to selectively increase hippocampal levels of human Abeta42 and Abeta40 in adult Wistar rats, allowing examination of the contribution of each to the cognitive deficits and pathology seen in AD.
  
  
  RESULTS
  Adeno-associated viral (AAV) vectors encoding BRI-Abeta cDNAs were generated resulting in high-level hippocampal expression and secretion of the specific encoded Abeta peptide. As a comparison the effect of AAV-mediated overexpression of APPsw was also examined. Animals were tested for development of learning and memory deficits (open field, Morris water maze, passive avoidance, novel object recognition) three months after infusion of AAV. A range of impairments was found, with the most pronounced deficits observed in animals co-injected with both AAV-BRI-Abeta40 and AAV-BRI-Abeta42. Brain tissue was analyzed by ELISA and immunohistochemistry to quantify levels of detergent soluble and insoluble Abeta peptides. BRI-Abeta42 and the combination of BRI-Abeta40+42 overexpression resulted in elevated levels of detergent-insoluble Abeta. No significant increase in detergent-insoluble Abeta was seen in the rats expressing APPsw or BRI-Abeta40. No pathological features were noted in any rats, except the AAV-BRI-Abeta42 rats which showed focal, amorphous, Thioflavin-negative Abeta42 deposits.
  
  
  CONCLUSIONS
  The results show that AAV-mediated gene transfer is a valuable tool to model aspects of AD pathology in vivo, and demonstrate that whilst expression of Abeta42 alone is sufficient to initiate Abeta deposition, both Abeta40 and Abeta42 may contribute to cognitive deficits.
authors.affiliation: Department of Molecular Medicine & Pathology, The University of Auckland, Auckland, New Zealand. t.lawlor@auckland.ac.nz
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Lawlor
authors.forename: Ross J
authors.initials: RJ
authors.lastname: Bland
authors.forename: Pritam
authors.initials: P
authors.lastname: Das
authors.forename: Robert W
authors.initials: RW
authors.lastname: Price
authors.forename: Vallie
authors.initials: V
authors.lastname: Holloway
authors.forename: Lisa
authors.initials: L
authors.lastname: Smithson
authors.forename: Bridget L
authors.initials: BL
authors.lastname: Dicker
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: During
authors.forename: Deborah
authors.initials: D
authors.lastname: Young
authors.forename: Todd E
authors.initials: TE
authors.lastname: Golde